Comparison of the Villalta Post Thrombotic Syndrome (PTS) Score in the Ipsilateral Versus Contralateral Leg After a First Unprovoked Deep Vein Thrombosis (DVT): Results From the REVERSE Study
Journal Articles
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
AbstractAbstract 1236Background:Post thrombotic syndrome (PTS) occurs in up to 40% of persons after a proximal DVT despite optimal anticoagulant therapy. International guidelines issued by the ISTH recommend assessing PTS with the Villalta scale, a clinical measure that incorporates ratings of 5 patient-rated venous symptoms and 6 clinician-rated venous signs in the leg ipsilateral to DVT (range of scores: 0–33). However, these signs and symptoms are not specific for PTS and their presence and relevance in the contralateral leg have not been studied. The objectives of this analysis were to assess the Villalta score in the contralateral leg and its correlation with the Villalta score in the ipsilateral leg after a first DVT.Methods:Using data from the REVERSE prospective multicentre cohort study, we compared the Villalta score in the ipsilateral vs. contralateral leg in patients with a first, unprovoked, unilateral proximal DVT 5–7 months previously. As per ISTH standards, PTS was considered present if the Villalta score was >4 in the leg ipsilateral to DVT. We also compared the distribution of the Villalta scale's signs and symptoms components in both legs in patients with PTS in the ipsilateral leg and Villalta score >4 in the contralateral leg.Results:Between October 2001 and March 2006, 664 patients with a first unprovoked venous thromboembolism (VTE) were enrolled in the REVERSE study after having received a 5–7 month course of anticoagulant therapy. The population for the present analysis consisted of the 360 REVERSE patients who had unilateral DVT as the index event, no previous secondary DVT or pulmonary embolism, and non-missing Villalta score data.Overall, mean Villalta score was higher in the ipsilateral than in the contralateral legs: 3.7 (interquartile range [IQR] 1.0 – 5.0) and 1.9 (IQR 0.0 – 3.0), respectively (paired t-test: p <0.0001).PTS was present in 31.9% (n=115) of patients. With increasing severity of venous ectasia in the contralateral leg, prevalence and severity of PTS gradually and significantly increased (both p<0.0001). Prevalence of any PTS increased from 25% (59/238) in the absence of contralateral venous ectasia to 100% (4/4) in the presence of severe contralateral venous ectasia, whereas the prevalence of severe PTS (Villalta score >15) increased from 0.9% (2/238) in patients without contralateral venous ectasia to 25% (1/4) in patients with severe contralateral venous ectasia.Villalta scores were strongly correlated in the ipsilateral and contralateral legs (r=0.68; R-Square: 0.4686; paired t-test: p<0.0001). Among the 13.9% (n=50) of patients with a Villalta score >4 in the contralateral leg, 92% (n=46) had PTS in the ipsilateral leg. Similarly, 40% (n=46) of patients with ipsilateral PTS had a Villalta score>4 in the contralateral leg. Among these 46 patients, the distribution of Villalta signs and symptoms components in both legs were similar: symptoms accounted for an average of 61% of the Villalta score in the ispsilateral leg and for 63% in the contralateral leg (paired t-test: p=0.3; 80% power to detect a paired difference of 7% using our standard deviation of 0.165 with a bilateral test at 5% alpha).Conclusions:Villalta scores in the ipsilateral and contralateral legs are strongly correlated. Almost half of patients with ipsilateral PTS had a Villalta score>4 in the contralateral leg. Among patients with Villalta score > 4 in both legs, distribution of venous signs and symptoms were similar between the two legs. This suggests that up to half of incident PTS diagnosed with the Villalta scale might in fact reflect pre-existing symptomatic chronic venous disease. Performing bilateral Villalta assessments after DVT both clinically and in PTS-related research could be of interest to distinguish PTS from previous primary venous disorders.Disclosures:Kahn: sanofi aventis: Honoraria, Research Funding; Leo Pharma: Honoraria.
